Codexis, Inc. (CDXS) Stock Grade

About Codexis, Inc.'s fundamentals

Codexis is a small-cap biotechnology company with a market capitalization of $146.3 million that is growing revenues at a healthy pace of 18.6% year-over-year. However, the company operates at a significant loss, with a net margin of -62.5%, and reported a net loss in its latest annual statement, meaning it is not yet profitable. The company does not pay a dividend, which is typical for growth-stage biotech firms that prioritize reinvesting capital into research and development. Profitability metrics like P/E ratio and return on equity are not applicable given the company's current loss-making status.